Plixorafenib Redefines BRAF Mutation Targeting

Plixorafenib Redefines BRAF Mutation Targeting

Plixorafenib Redefines BRAF Mutation Targeting

Plixorafenib Redefines BRAF Mutation Targeting

Client:

ForeBio is a precision oncology company developing targeted therapies for difficult-to-treat cancers. Its lead asset, plixorafenib, is a next-generation BRAF inhibitor designed to address a broad range of BRAF mutations beyond Class I (V600) without causing paradoxical activation of the MAPK cascade.

ForeBio is a precision oncology company developing targeted therapies for difficult-to-treat cancers. Its lead asset, plixorafenib, is a next-generation BRAF inhibitor designed to address a broad range of BRAF mutations beyond Class I (V600) without causing paradoxical activation of the MAPK cascade.

ForeBio is a precision oncology company developing targeted therapies for difficult-to-treat cancers. Its lead asset, plixorafenib, is a next-generation BRAF inhibitor designed to address a broad range of BRAF mutations beyond Class I (V600) without causing paradoxical activation of the MAPK cascade.

ForeBio is a precision oncology company developing targeted therapies for difficult-to-treat cancers. Its lead asset, plixorafenib, is a next-generation BRAF inhibitor designed to address a broad range of BRAF mutations beyond Class I (V600) without causing paradoxical activation of the MAPK cascade.

Client:

Project Goal

Project Goal

Project Goal

Project Goal

To support ForeBio’s investor relations, corporate communications, and industry presentations, we developed a concise mechanism-of-action (MoA) animation for plixorafenib that illustrates its competitive advantages. By balancing high-detail molecular visualization with accessibility, the animation enabled both scientific and non-scientific stakeholders to quickly grasp the key takeaways.

See full animation.

To support ForeBio’s investor relations, corporate communications, and industry presentations, we developed a concise mechanism-of-action (MoA) animation for plixorafenib that illustrates its competitive advantages. By balancing high-detail molecular visualization with accessibility, the animation enabled both scientific and non-scientific stakeholders to quickly grasp the key takeaways.

See full animation.

To support ForeBio’s investor relations, corporate communications, and industry presentations, we developed a concise mechanism-of-action (MoA) animation for plixorafenib that illustrates its competitive advantages. By balancing high-detail molecular visualization with accessibility, the animation enabled both scientific and non-scientific stakeholders to quickly grasp the key takeaways.

See full animation.

To support ForeBio’s investor relations, corporate communications, and industry presentations, we developed a concise mechanism-of-action (MoA) animation for plixorafenib that illustrates its competitive advantages. By balancing high-detail molecular visualization with accessibility, the animation enabled both scientific and non-scientific stakeholders to quickly grasp the key takeaways.

See full animation.

RAS, BRAF, MEK and ERK molecules interact with each other inside the cell cytoplasm
RAS, BRAF, MEK and ERK molecules interact with each other inside the cell cytoplasm
RAS, BRAF, MEK and ERK molecules interact with each other inside the cell cytoplasm
RAS, BRAF, MEK and ERK molecules interact with each other inside the cell cytoplasm

Paradoxical activation of the MAPK cascade

Paradoxical activation of the MAPK cascade

Paradoxical activation of the MAPK cascade

Paradoxical activation of the MAPK cascade

Class III Dimers: RAS, BRAF, and CRAF

Class III Dimers: RAS, BRAF, and CRAF

Class III Dimers: RAS, BRAF, and CRAF

Class III Dimers: RAS, BRAF, and CRAF

Plixorafenib molecule inside the binding pocket on the BRAF kinase
Plixorafenib molecule inside the binding pocket on the BRAF kinase
Plixorafenib molecule inside the binding pocket on the BRAF kinase
Plixorafenib molecule inside the binding pocket on the BRAF kinase

Plixorafenib targeting mutated BRAF

Plixorafenib targeting mutated BRAF

Plixorafenib targeting mutated BRAF

Plixorafenib targeting mutated BRAF

“Excellent collaboration to complete a beautiful final animation!”

“Excellent collaboration to complete a beautiful final animation!”

“Excellent collaboration to complete a beautiful final animation!”

“Excellent collaboration to complete a beautiful final animation!”

Photo of Ted Everson
Photo of Ted Everson
Photo of Ted Everson

Executive Director and Lead of Medical Affairs

Executive Director and
Lead of Medical Affairs

Short insertion in the DNA molecule
Short insertion in the DNA molecule
Short insertion in the DNA molecule
Short insertion in the DNA molecule

BRAF dimers interact with RAS proteins in the beginning of the MAPK signaling cascade

BRAF dimers interact with RAS proteins in the beginning of the MAPK signaling cascade

BRAF dimers interact with RAS proteins in the beginning of the MAPK signaling cascade

BRAF dimers interact with RAS proteins in the beginning of the MAPK signaling cascade

3D molecular visualization of plixorafenib binding to the BRAF-CRAF heterodimer
3D molecular visualization of plixorafenib binding to the BRAF-CRAF heterodimer
3D molecular visualization of plixorafenib binding to the BRAF-CRAF heterodimer
3D molecular visualization of plixorafenib binding to the BRAF-CRAF heterodimer

Plixorafenib targets BRAF-CRAF heterodimers

Plixorafenib targets BRAF-CRAF heterodimers

Plixorafenib targets BRAF-CRAF heterodimers

Plixorafenib targets BRAF-CRAF heterodimers

Destruction of Cancer cells

Destruction of Cancer cells

Destruction of Cancer cells

Destruction of Cancer cells

The Process

The Process

The Process

The Process

Animation type:

Animation type:

Animation type:

Animation type:

3D + High End 3D

3D + High End 3D

3D + High End 3D

3D + High End 3D

Project timline:

Project timline:

Project timline:

Project timline:

7 weeks

7 weeks

7 weeks

7 weeks

Review:

Review:

Review:

Review:

3 zoom calls + 7 e-mail feedback sessions

3 zoom calls + 7 e-mail feedback sessions

3 zoom calls + 7 e-mail feedback sessions

3 zoom calls + 7 e-mail feedback sessions

Team:

Find out which of our 26 scientific animation options works best for investor relations and communications:

Find out which of our 26 scientific animation options works best for investor relations and communications:

Find out which of our 26 scientific animation options works best for investor relations and communications:

Find out which of our 26 scientific animation options works best for investor relations and communications:

To accurately visualize BRAF inhibitors and their effects, we combined high-end molecular modeling with clear, structured storytelling. The animation depicted how plixorafenib interacts with the BRAF signaling cascade, ensuring scientific accuracy while maintaining accessibility.


Communicating the mechanism of action and competitive advantages of plixorafenib is particularly challenging, as BRAF targeting involves significant nuances, including paradoxical activation of the MAPK cascade and the presence of different RAF mutation classes and dimerization states. To address this complexity, we applied several complementary approaches to ensure an accurate and effective communication asset.


High-End 3D Molecular Animation: We used molecular dynamics simulations and structural modeling to depict precise protein conformations, inhibitor binding, and phosphorylation events. This project employed a more detailed molecular approach than our previous conceptual animations.


Visual Overlays: Simplified schematic 2D overlays mirrored the molecular sequences, breaking down key interactions for easier comprehension. These were combined with a color-coded tagging system to consistently highlight critical molecular components.


Brand Integration: The animation aesthetics were aligned with ForeBio’s corporate style guide, refining protein stylization to match the brand while preserving scientific precision.

To accurately visualize BRAF inhibitors and their effects, we combined high-end molecular modeling with clear, structured storytelling. The animation depicted how plixorafenib interacts with the BRAF signaling cascade, ensuring scientific accuracy while maintaining accessibility.


Communicating the mechanism of action and competitive advantages of plixorafenib is particularly challenging, as BRAF targeting involves significant nuances, including paradoxical activation of the MAPK cascade and the presence of different RAF mutation classes and dimerization states. To address this complexity, we applied several complementary approaches to ensure an accurate and effective communication asset.


High-End 3D Molecular Animation: We used molecular dynamics simulations and structural modeling to depict precise protein conformations, inhibitor binding, and phosphorylation events. This project employed a more detailed molecular approach than our previous conceptual animations.


Visual Overlays: Simplified schematic 2D overlays mirrored the molecular sequences, breaking down key interactions for easier comprehension. These were combined with a color-coded tagging system to consistently highlight critical molecular components.


Brand Integration: The animation aesthetics were aligned with ForeBio’s corporate style guide, refining protein stylization to match the brand while preserving scientific precision.

To accurately visualize BRAF inhibitors and their effects, we combined high-end molecular modeling with clear, structured storytelling. The animation depicted how plixorafenib interacts with the BRAF signaling cascade, ensuring scientific accuracy while maintaining accessibility.


Communicating the mechanism of action and competitive advantages of plixorafenib is particularly challenging, as BRAF targeting involves significant nuances, including paradoxical activation of the MAPK cascade and the presence of different RAF mutation classes and dimerization states. To address this complexity, we applied several complementary approaches to ensure an accurate and effective communication asset.


High-End 3D Molecular Animation: We used molecular dynamics simulations and structural modeling to depict precise protein conformations, inhibitor binding, and phosphorylation events. This project employed a more detailed molecular approach than our previous conceptual animations.


Visual Overlays: Simplified schematic 2D overlays mirrored the molecular sequences, breaking down key interactions for easier comprehension. These were combined with a color-coded tagging system to consistently highlight critical molecular components.


Brand Integration: The animation aesthetics were aligned with ForeBio’s corporate style guide, refining protein stylization to match the brand while preserving scientific precision.

To accurately visualize BRAF inhibitors and their effects, we combined high-end molecular modeling with clear, structured storytelling. The animation depicted how plixorafenib interacts with the BRAF signaling cascade, ensuring scientific accuracy while maintaining accessibility.


Communicating the mechanism of action and competitive advantages of plixorafenib is particularly challenging, as BRAF targeting involves significant nuances, including paradoxical activation of the MAPK cascade and the presence of different RAF mutation classes and dimerization states. To address this complexity, we applied several complementary approaches to ensure an accurate and effective communication asset.


High-End 3D Molecular Animation: We used molecular dynamics simulations and structural modeling to depict precise protein conformations, inhibitor binding, and phosphorylation events. This project employed a more detailed molecular approach than our previous conceptual animations.


Visual Overlays: Simplified schematic 2D overlays mirrored the molecular sequences, breaking down key interactions for easier comprehension. These were combined with a color-coded tagging system to consistently highlight critical molecular components.


Brand Integration: The animation aesthetics were aligned with ForeBio’s corporate style guide, refining protein stylization to match the brand while preserving scientific precision.

Why did we use this
animation type?

Why did we use
this animation type?

Why did we use this
animation type?

Why did we use this
animation type?

We used detailed 3D molecular animation to precisely depict plixorafenib’s interactions within the BRAF signaling cascade. Although the project did not formally adopt a full high-end style, we applied our molecular modeling expertise to reconstruct complete structures of key proteins, including unresolved intrinsically disordered regions. Molecular modeling and simulations ensured scientific accuracy, while 2D overlays simplified complex interactions for broader audiences. Cinematic techniques—such as dynamic lighting and seamless transitions—enhanced engagement, and brand-aligned visuals reflected ForeBio’s well-developed corporate style, which extends beyond color to include specific preferences for 3D visual aesthetics.

We used detailed 3D molecular animation to precisely depict plixorafenib’s interactions within the BRAF signaling cascade. Although the project did not formally adopt a full high-end style, we applied our molecular modeling expertise to reconstruct complete structures of key proteins, including unresolved intrinsically disordered regions. Molecular modeling and simulations ensured scientific accuracy, while 2D overlays simplified complex interactions for broader audiences. Cinematic techniques—such as dynamic lighting and seamless transitions—enhanced engagement, and brand-aligned visuals reflected ForeBio’s well-developed corporate style, which extends beyond color to include specific preferences for 3D visual aesthetics.

We used detailed 3D molecular animation to precisely depict plixorafenib’s interactions within the BRAF signaling cascade. Although the project did not formally adopt a full high-end style, we applied our molecular modeling expertise to reconstruct complete structures of key proteins, including unresolved intrinsically disordered regions. Molecular modeling and simulations ensured scientific accuracy, while 2D overlays simplified complex interactions for broader audiences. Cinematic techniques—such as dynamic lighting and seamless transitions—enhanced engagement, and brand-aligned visuals reflected ForeBio’s well-developed corporate style, which extends beyond color to include specific preferences for 3D visual aesthetics.

We used detailed 3D molecular animation to precisely depict plixorafenib’s interactions within the BRAF signaling cascade. Although the project did not formally adopt a full high-end style, we applied our molecular modeling expertise to reconstruct complete structures of key proteins, including unresolved intrinsically disordered regions. Molecular modeling and simulations ensured scientific accuracy, while 2D overlays simplified complex interactions for broader audiences. Cinematic techniques—such as dynamic lighting and seamless transitions—enhanced engagement, and brand-aligned visuals reflected ForeBio’s well-developed corporate style, which extends beyond color to include specific preferences for 3D visual aesthetics.

Outcome:

Outcome:

Outcome:

Outcome:

The animation delivered a clear and engaging depiction of BRAF inhibitors for both scientific and business audiences. By blending detailed 3D modeling with intuitive 2D elements, it became a versatile asset for investor decks, corporate presentations, and conferences. Successfully deployed at a key congress, the animation reinforced ForeBio’s messaging and helped drive interest in its oncology approach.

The animation delivered a clear and engaging depiction of BRAF inhibitors for both scientific and business audiences. By blending detailed 3D modeling with intuitive 2D elements, it became a versatile asset for investor decks, corporate presentations, and conferences. Successfully deployed at a key congress, the animation reinforced ForeBio’s messaging and helped drive interest in its oncology approach.

The animation delivered a clear and engaging depiction of BRAF inhibitors for both scientific and business audiences. By blending detailed 3D modeling with intuitive 2D elements, it became a versatile asset for investor decks, corporate presentations, and conferences. Successfully deployed at a key congress, the animation reinforced ForeBio’s messaging and helped drive interest in its oncology approach.

The animation delivered a clear and engaging depiction of BRAF inhibitors for both scientific and business audiences. By blending detailed 3D modeling with intuitive 2D elements, it became a versatile asset for investor decks, corporate presentations, and conferences. Successfully deployed at a key congress, the animation reinforced ForeBio’s messaging and helped drive interest in its oncology approach.

Full animation

Full animation

Full animation

Full animation

Contact us

Contact us

Contact us

Contact us

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor,
New York, NY 10281, USA

Social networks

LinkedIn Logo
Vimeo Logo

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor, New York, NY 10281, USA

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor,
New York, NY 10281, USA

Social networks

LinkedIn Logo
Vimeo Logo

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor,
New York, NY 10281, USA

Social networks

LinkedIn Logo
Vimeo Logo

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science Logo
Visual Science Logo
Visual Science Logo
Visual Science Logo
Visual Science Logo
Visual Science Logo